Lauxera Closes Oversubscribed €520M Fund II to Push European Healthtech Into the US Market
TL;DR
Paris and San Francisco-based growth investor Lauxera Capital Partners closed Lauxera Growth II at €520 million, surpassing the €500 million hard cap and nearly doubling its 2023 debut fund. With a 90%-plus re-up rate from existing LPs and a thesis built around pushing European healthtech into the United States, this is the most credible European healthcare growth raise of 2026 so far.
Key Takeaways
The 90%+ re-up rate is the real signal. In a 2026 LP environment where re-ups are routinely getting trimmed and emerging managers are getting frozen out, Lauxera held nearly every existing LP and added new commitments from Morgan Stanley IM, Sagard, Flextone, Swen Capital Partners, and Malakoff Humanis. That kind of LP loyalty is rare and tells you more about Fund I performance than any public mark.
Europe-to-US is the thesis, not Europe alone. Lauxera's pitch is built explicitly around helping commercial-stage European healthtech companies scale in the US market. The San Francisco office is not a vanity outpost. It is the value-add that justifies the fund's check sizes and the LP base's willingness to pay a Tier-1 fee structure.
€20M to €50M check sizes put Lauxera in a thin part of the European stack. Below that range, Europe is crowded with healthtech early-stage funds. Above it, US growth funds dominate. The €20M to €50M slot at the European commercial-scale-up moment is where founders have historically had to choose between dilution at home or transatlantic chaos. Lauxera is buying that slot.
Bpifrance and EIF anchoring matters beyond the capital. Sovereign and quasi-sovereign anchors give Lauxera procurement access at European hospital systems and regulatory tailwinds that a pure private LP base cannot replicate. For founders selling into reimbursement-driven markets, that is a multi-quarter accelerant.
Fund Overview
Fund Name: Lauxera Growth II
Fund Size: €520 million (oversubscribed, broke €500M hard cap)
Stage: Growth equity, commercial-stage
Check Size: €20M to €50M, both minority and majority
Geography: European headquartered companies with US expansion ambitions
Focus: Medical devices, pharma and medtech services, digital health, healthcare data and software, life science tools and diagnostics
Key LPs: Morgan Stanley Investment Management, Bpifrance, European Investment Fund (EIF), Sagard, Flextone, Swen Capital Partners, Malakoff Humanis, plus new LPs from DACH, Nordics, Latin America, and the US
Why This Fund Matters
European healthtech has a structural problem that Lauxera is built to solve. Commercial-stage European medtech and digital health companies routinely outperform their US peers on capital efficiency, regulatory rigor, and clinical evidence, then stall out when they try to crack the US market. The story is the same every cycle: a Swiss device company gets FDA clearance but cannot crack reimbursement, a German digital health company has 200 hospital deployments at home but cannot get a Cleveland Clinic pilot, a French diagnostics company is dominant in five EU countries but burns 18 months on the US sales motion.
Growth equity funds rarely solve this because they are either too geographic (US funds parachuting in for the round) or too small (European funds that follow on without the US operating bench). Lauxera's bet is that running a dedicated SF office staffed with US healthcare commercial talent, paired with a Paris team that understands European regulatory and reimbursement dynamics, creates a structural advantage. The early evidence supports it: Acandis (German neurovascular) and Antaros Medical (Swedish imaging CRO) are both classic European medtech assets with US scale potential.
Doubling fund size while maintaining check size discipline is the right call. Going from €270M to €520M lets the firm run a tighter portfolio of 12 to 15 companies with more reserve capital per name, which matters in healthcare where commercial expansion can swallow follow-on rounds that smaller funds cannot anchor.
The European healthtech tailwind is real. EU MDR has finally settled, NHS digital procurement is opening, France's PECAN reimbursement pathway is live, and Germany's DiGA framework is producing scaled exits. The infrastructure for commercial-stage European healthtech is the best it has ever been, and the funds that can navigate both EU and US commercial dynamics will harvest the next decade.
The Team
Lauxera was founded by a partnership group with deep healthcare operating and investment backgrounds across France and the US. The team's track record in Fund I included exits and IPOs in the medtech and digital health space, though the firm has not publicly broken out IRR figures. The San Francisco team is led by partners with prior experience at US growth healthcare funds, which is why the Europe-to-US bridging strategy is credible rather than aspirational.
Early Portfolio
Lauxera Growth II has already deployed into two companies: a minority position in Acandis, a German neurovascular device innovator focused on stroke intervention, and a majority position in Antaros Medical, a Swedish advanced imaging contract research organization that supports pharmaceutical trials in cardiometabolic and oncology indications. Both fit the profile precisely: commercial-stage, European-headquartered, US-expansion-ready, and reimbursable.
What This Means for Founders
If you are running a commercial-stage European healthtech company with €5M+ in revenue and a credible US expansion thesis, Lauxera should be on your shortlist for Series C and growth equity rounds. The value-add is real and operationally measurable, not theoretical. Expect a deep diligence process that scrutinizes US reimbursement strategy and commercial team build-out as hard as it scrutinizes the technology.
The firm's willingness to take majority positions is important. For founders considering a strategic sale versus a growth round, Lauxera can credibly offer either path, which gives boards optionality at a moment when most growth funds are stuck doing minority financings.
Fund Momentum Take
This is the European healthtech raise of the year, and we think the market is still underestimating the franchise Lauxera is building. The transatlantic growth thesis is differentiated enough to justify a doubled fund size, the LP loyalty signal is unusually strong, and the early Fund II deployments suggest discipline rather than rush-to-deploy.
The main risk is concentration. A 12 to 15 company portfolio with €20M to €50M average checks means each position is materially impactful. If two or three of the early bets struggle in the US transition, the fund's overall return profile compresses meaningfully. Lauxera's pipeline diligence and pacing will need to remain disciplined, especially as US healthcare M&A markets remain choppy.
Our bet: Lauxera positions itself as the default Series C and growth round for top-quartile European healthtech in this vintage. By 2028 the firm is raising Fund III at €700M+ with a markedly broader US LP base, and at least one Fund I exit prints a 5x+ return that resets European healthcare benchmarks.
Frequently Asked Questions
How big is Lauxera Growth II?
The fund closed at €520 million on May 19, 2026, exceeding its €500 million hard cap. That is nearly double the size of Lauxera's debut fund.
What does Lauxera invest in?
Lauxera writes €20M to €50M checks into commercial-stage European healthtech companies, including medical devices, pharma and medtech services, digital health, healthcare data and software, and life science tools and diagnostics.
Who are the LPs?
LPs include Morgan Stanley Investment Management, Bpifrance, European Investment Fund (EIF), Sagard, Flextone, Swen Capital Partners, and Malakoff Humanis. New investors joined from the DACH region, Nordics, Latin America, and the US.
Where is Lauxera based?
The firm has offices in Paris and San Francisco. The dual-location model is core to its thesis of helping European healthtech companies scale in the US market.
What companies has Lauxera invested in so far?
From Fund II, Lauxera has invested in Acandis, a German neurovascular device company, and Antaros Medical, a Swedish advanced imaging CRO.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.